To many, 2014 is a year of renewed energy and growth. Global partnerships at all levels are breaking down barriers to innovation, as the convergence of health and technology starts to shape new solutions for patients around the world. In 2015, what new areas – scientifically, technologically, and geographically — might we expect to see these partnerships blossom, and how might global collaborations propel the industry as whole?
WuXi Global Forum 2015, “A Celebration of Global Partnerships”, continues to move the conversation forward to promote new thinking on a global stage as we strive to find better solutions for patients.
Ge Li, Chairman and CEO, WuXi AppTec
Moderator: Richard Soll, SVP and Head of International Discovery Service Unit, WuXi AppTec
Michael Varney, EVP and Head of Research and Early Development, Genentech
Steve Yang, EVP and COO, WuXi AppTec
Hans Bishop, CEO and President, Juno Therapeutics
Robert Urban, Head, Johnson & Johnson Innovation, Boston
David Flores, Co-founder, President and CEO, BioCentury
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances and Head of PR and Corporate Communications. Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to nearly 50 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS) and a member of ACS national committee on Chemistry and Public Affairs. She is also a member of the Advisory Council of UCSD IRPS 21th Century China Program, and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.
Ms. Gail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Gail brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Gail served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology. Gail practiced management and strategy consulting with Bain & Co. She serves on the boards of NovaBay Pharmaceuticals, Opexa Therapeutics, BayBio, the Mayor’s Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. Gail received a BS in business from UC Berkeley and an MBA from Harvard Business School.
Mr. David Flores has devoted more than 25 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. Mr. Flores is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, Mr. Flores and BioCentury Co-Founder, Chairman & Editor-in-Chief Ms. Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury’s ongoing contributions to the industry.
Dr. Ge Li is the founder, Chairman, and CEO of WuXi AppTec Co., Ltd, a NYSE-listed global R&D capability and technology platform company (NYSE: WX) serving the pharmaceutical, biotechnology, and medical device industries. Dr. Li studied at Peking University as an undergraduate and received his Ph.D. in Chemistry from Columbia University. He began his career
in 1993 as one of the founding scientists at Pharmacopeia, Inc. (NASDAQ: PCOP). In 2000, Dr. Li moved back to Shanghai to found WuXi PharmaTech and has been its Chairman and CEO. He successfully managed to grow the company from a small start-up to a global organization with 9000 employees and 5 million square feet of office, laboratory and manufacturing space in China and the United States.
Dr. Li’s achievements have won him numerous prestigious awards and honors, including 2014 Top Contributors to China’s Outsourcing Industry, 2014 CABS K. Fong Award in Life Sciences, 2013 Shanghai Science & Technology Outstanding Contribution Award, 2013 Pudong Science & Technology Innovation Award, 2013 Top Contributors to China’s Outsourcing Industry, 2012 Boston Biotech CEO Conference Life Achievement Award, 2011 China Healthcare Industry Innovative
Leaders Award, 2011 Top Contributors to China’s Outsourcing Industry Award, 2011 BayHelix Lifetime Achievement Award, 2010 San Diego Bio-Pharma Achievement Award, 2009 The 60 Most Influential People during 60 Years Pharmaceutical Development in China, 2008 Forbes 25 Notable Chinese-Americans, the Most Innovative Leader of Chinese Enterprises in 2008 together with WuXi AppTec the Most Innovative Company in China, 2007 China Top 10 Influential Entrepreneurs,
2007 Ernst & Young Entrepreneur of the Year China Award, 2006 China Top Ten Talents (Science & Technology) Award. In 2005 Dr. Ge Li was featured on the cover page of Red Herring magazine August issue, and honored with Distinguished Entrepreneur Award from Overseas Chinese Affairs Office of The State Council of People’s Republic of China.
Dr. Steve Yang is Executive Vice President and Chief Operating Officer of WuXi AppTec. WuXi AppTec (NYSE: WX) is a leading
global pharmaceutical, biopharmaceutical, and medical device R&D capability and technology open access platform company with operations in China and the United States.
Dr. Yang is a pharmaceutical industry leader recognized for building
R&D capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships
in China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer’s global R&D strategic management group based in the United States. Before joining Pfizer, Dr. Yang held a number of leadership positions at IntraBiotics Pharmaceuticals, a U.S.-based biotech company. He also worked for Strategic Decisions Group, a strategy consulting firm for Fortune 100 companies.
Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco, USA. He started
his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude in Biology from Michigan
Technological University, USA. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese
life science business leaders, and served as the chairman of the board for two terms.
Mr. Hans Bishop is one of our co-founders and has served as our Chief Executive Officer and a member of our Board of Directors since September 2013. Mr. Bishop has also served as a member of the Board of Directors of Avanir Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, since May 2012. Mr. Bishop previously served as Chairman of the Board of Genesis Biopharma, Inc., a biotechnology company, from January 2012 until November 2012. From February 2012 until October 2012, Mr. Bishop was the Chief Operating Officer of PhotoThera, Inc., a late-stage medical device company owned by Warburg Pincus, and he continued working with Warburg Pincus as an Executive in Residence until October 2013. Mr. Bishop previously served as Executive Vice President and Chief Operating Officer at Dendreon Corporation, a cancer cell therapy company, from January 2010 to September 2011.
Mr. Bishop has also served as the President of the Specialty Medicine Business at Bayer Healthcare Pharmaceuticals, Inc.
from December 2006 to January 2010, where he was responsible for a diverse portfolio of neurology, oncology, and hematology products. Mr. Bishop was employed by Chiron Corporation as Senior Vice President of Global Commercial Operations until its sale to Novartis Corporation. Mr. Bishop received a B.Sc. in Chemistry from Brunel University in London.
Dr. Robert Urban is Head of the Johnson & Johnson Innovation, Boston. He joined the Johnson & Johnson Family of Companies from the Massachusetts Institute of Technology, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. In this leadership role, Robert worked to build the Koch Institute into new standard for interdisciplinary diseasefocused research via an expanding, highly-effective, relationship network with other academic oncology centers, industrial partners, cancer-focused philanthropists and investors. During Robert’s tenure, the Koch Institute launched seventeen start-up companies and its technology was the source of over 50 outlicensing
Robert was recruited to MIT from Acretia Inc. – a product acquisition and out-licensing company where he was the President and CEO. During his time at Acretia Inc. the organization conducted technical due diligence on more than 280 product opportunities and completed the acquisition of three distinct product lines. Prior to this, Robert held a variety of business development and clinical development roles in the pharmaceutical industry. He has worked in the areas of oncology, HPV, anti-inflammatory and infectious diseases. His experience includes clinical product development, operations oversight, licensing and acquisitions, capital fund raising, company creation, and building relationships with key thought-leaders.